Jasper Therapeutics Reports Encouraging Results from SPOTLIGHT Phase 1b/2a Study of Briquilimab for Chronic Inducible Urticaria
14/6 16:10
Jasper Therapeutics reports promising SPOTLIGHT study results for briquilimab in treating chronic inducible urticaria with favorable safety outcomes....